API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.
Lead Product(s): Dabigatran Etexilate Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dabigatran Etexilate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Pradaxa-Generic (dabigatran etexilate) is a USFDA approved direct thrombin inhibitor, which is indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation.
Lead Product(s): Dabigatran Etexilate Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Pradaxa-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2024
Details:
Dabigatran etexilate reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5 to 10 days
Lead Product(s): Dabigatran Etexilate Mesylate
Therapeutic Area: Neurology Product Name: Pradaxa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran's established and well-documented safety and efficacy profile in adults
Lead Product(s): Dabigatran Etexilate Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Pradaxa
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020